Excellagen® is an Advanced, Wound Care Management Platform

For professional use only; designated as “skin substitutes” per CMS. MAC reimbursement process

• Formulated fibrillar Collagen (2.6%) Wound Conforming Matrix

• High molecular weight


Excellagen Highlights

Excellagen is FDA 510(K) cleared for 17 wound types

Intellectual properties and global rights of Excellagen® except China, Russia and CIS

R&D company spent over $20 million prior to approval

Received Patent on October 10, 2017

Has a unique Healthcare Common Procedure Coding System (HCPCS) Code – Q4149 https://hcpcs.codes/q-codes/Q4149/

Clinical data show significant tissue growth, accelerated healing response and positive wound closure

Safe and effective

No mixing, no sutures, no staples, no thawing

Over $20 million invested and completed

Viscosity optimized for dripless wound coverage

Wound Conforming Matrix that completely covers the wound bed and fills all voids

Pre-filled, ready to use syringes with flexible applicator tips

Three syringe sizes: 0.5cc, 0.8cc and 3.0cc to cover a variety of wound sizes

Refrigerated storage

Treatment at only one-week intervals

Immediately activates human platelets triggering release of Platelet-Derived Growth Factor (PDGF) a key

Accelerates granulation tissue growth in “non-healing wounds”

Excellagen is categorized as Cellular and/or Tissue Based Product (CTP)


Excellagen has can serve as an Enabling Delivery Platform for pluripotent stem cells, antimicrobial agents, small molecule drugs, DNA-Based Biologics, conditioned cell media and peptides.



Future products focusing on innovative therapies in bone and joint regeneration comprise current pipeline. The company’s mission is to become a significant force in regenerative medicine and Innovate the Science of Healing.

1001 6th Ave, 2nd Fl, New York, NY 10018
1-844 -WOUNDS4

1001 6th Ave, 2nd Fl, New York, NY 10018
1-844 -WOUNDS4